Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | Director · President | March 16, 2020 | March 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Whitehawk Therapeutics, Inc.
Report date March 16, 2020 · Filed March 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2030-03-16 | Direct | 155,000 |
Reported balance
After 2020-03-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-16 · Grant · Acquired 155,000 · Balance 155,000 F1: Options exercisable as to 1/4th on March 16, 2021 and an additional 1/48th monthly thereafter until March 16, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Options exercisable as to 1/4th on March 16, 2021 and an additional 1/48th monthly thereafter until March 16, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2020 Filed Mar 18, 2020 22:14 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0000899243-20-008925 · doc4.xml · derivative · entry 1 Gardner Joseph H. · CIK 0001700816 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: Options exercisable as to 1/4th on March 16, 2021 and an additional 1/48th monthly thereafter until March 16, 2024. Read SEC document |
| July 10, 2019 Filed Jul 10, 2019 22:03 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 5,000 | $0.81 | $4,073.50 |
DisclosureSEC source: 0000899243-19-019449 · doc4.xml · nonDerivative · entry 1 Gardner Joseph H. · CIK 0001700816 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,019 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.80 to $0.8217, inclusive. The reporting person undertakes to provide to Aerpio Pharmaceuticals, Inc., any security holder of Aerpio Pharmaceuticals, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2019 Filed Jul 8, 2019 21:51 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 5,000 | $0.90 | $4,485.00 |
DisclosureSEC source: 0000899243-19-019320 · doc4.xml · nonDerivative · entry 1 Gardner Joseph H. · CIK 0001700816 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,019 Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:14 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 349,350 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0000899243-19-013768 · doc4.xml · derivative · entry 1 Gardner Joseph H. · CIK 0001700816 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,350 Underlying: Common Stock · 349,350 shares Expires 2029-05-14 F1 · derivative.exercise_date: 50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:53 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000899243-19-004275 · doc4.xml · derivative · entry 1 Gardner Joseph H. · CIK 0001700816 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-02-15 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| December 12, 2018 Filed Feb 13, 2019 21:41 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GiftCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-003439 · doc5.xml · nonDerivative · entry 2 Gardner Joseph H. · CIK 0001700816 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 150,000 F1 · balance_after: On December 12, 2018, the reporting person gifted these shares to a family trust for the benefit of the reporting person's children. The reporting person's sibling is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: On December 12, 2018, the reporting person gifted these shares to a family trust for the benefit of the reporting person's children. The reporting person's sibling is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 12, 2018 Filed Feb 13, 2019 21:41 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GiftCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-003439 · doc5.xml · nonDerivative · entry 1 Gardner Joseph H. · CIK 0001700816 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,019 Read SEC document |
| April 23, 2018 Filed Apr 26, 2018 00:22 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000899243-18-010744 · doc4.xml · derivative · entry 1 Gardner Joseph H. · CIK 0001700816 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-04-23 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:09 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $5.50 Strike: $5.50 | $742,500.00 |
DisclosureSEC source: 0000899243-17-029053 · doc4.xml · derivative · entry 1 Gardner Joseph H. · CIK 0001700816 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,000 shares Expires 2027-12-14 F1 · derivative.exercise_date: Option grant fully exercisable on July 1, 2018 Read SEC document |
| March 15, 2017 Filed Mar 18, 2017 00:39 UTC | Whitehawk Therapeutics, Inc. NONE · Entity 6074 | PurchaseCommon Stock | 99,996 | $5.00 | $499,980.00 |
DisclosureSEC source: 0000899243-17-008156 · doc4.xml · nonDerivative · entry 1 Gardner Joseph H. · CIK 0001700816 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,019 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.